Johnson & Johnson said it would begin testing an Ebola-virus vaccine in humans in January and could have 250,000 doses available in May, if health authorities deem it safe and promising enough to distribute more broadly.
NEW YORK/DALLAS (Reuters) - Johnson & Johnson was found not liable by a Texas jury on Thursday in the first case to go to trial over whether Pinnacle hip implants made by the company's DePuy Orthopedics unit were defective.
Microbial contamination in samples of the blockbuster blood thinner Xarelto - used to prevent blood clots and strokes - caused Johnson & Johnson's Janssen unit to recall 13,500 bottles of the drug this week. The recall comes shortly after several new ...
Johnson & Johnson is to start testing its Ebola vaccine candidate in January after the World Health Organisation (WHO) and world leaders asked it and other companies to accelerate their research programmes.
In spite of divesting some of its noncore businesses and experiencing negative currency translation headwinds, Johnson & Johnson managed to grow its revenue by better than 5%, while its EPS improved by 10%. On the surface it looked like a great report.
NEW YORK (TheStreet) -- Shares of Johnson & Johnson (JNJ) are up 1.61% to $101.98 in pre-market trade after it was reported this morning that the company plans to have 250,000 doses of an experimental Ebola vaccine ready for use in clinical trials in ...
Johnson & Johnson has similar incubators in San Diego, San Francisco and Boston. And although Houston has long been known as a medical hub, with nearly $1 billion worth of research at the Texas Medical Center annually, something's been missing.